<p>Phase 1 trial will include 16 patients ages 60 to 85 years who have early, symptomatic Alzheimer disease but are otherwise in good health</p>
<p>Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria</p>